Chat with us, powered by LiveChat

Diabetes Devices and Drugs Market (Type - Devices, and Drugs; End User - Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Centers, and Self-care): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Diabetes Devices and Drugs Market (Type - Devices, and Drugs; End User - Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Centers, and Self-care): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR01392 Category: Healthcare & Medical Devices Published: March, 2024

A recent report published by Infinium Global Research on diabetes devices and drugs market provides in-depth analysis of segments and sub-segments in the global as well as regional diabetes devices and drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional diabetes devices and drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global diabetes devices and drugs market.

Market Insight:

The global diabetes devices and drugs market was valued at USD 159.1 billion in 2022 and is expected to reach USD 383.6 billion in 2030, with a CAGR of 10.18% during the forecast period 2023-2030.

The diabetic devices and medications market is the segment of the healthcare industry that focuses on the development, manufacturing, and distribution of pharmaceuticals and medical devices that are specially designed for the management and treatment of diabetes. This market includes a wide variety of products such as insulin pumps, injectable pharmaceuticals intended to control blood sugar levels, insulin pens, continuous glucose monitoring, and oral treatments. Due to constant innovation to provide patients with more sophisticated, user-friendly, and efficient solutions, this market has grown significantly due to the increasing global prevalence of diabetes. It's a profitable industry where businesses compete to provide innovative tools and drugs to meet the demands of people with diabetes, simultaneously aiming for greater health and a higher standard of living.

The growing global prevalence of diabetes significantly drives market growth. More efficient, practical, and easily accessible tools and medications are needed to manage diabetes as the number of people with the disease keeps rising. An aging population, unhealthy dietary habits, sedentary lifestyle, and changing habits all contribute to this demand. The requirement for improved diabetes management solutions, including enhanced drug therapies, sophisticated insulin delivery systems, and non-invasive monitoring devices, is driving the development and commercial success of products in this market. Additionally, an increase in product approvals and launches is expected to drive the anticipated expansion of the global market for diabetic medications and devices. For instance, in December 2022, Dexcom, Inc., a firm specializing in the development, manufacturing, production, and distribution of continuous glucose monitoring systems for diabetes management, approved the receipt of U.S. Food and Drug Administration (FDA) clearance for its advanced DexcomG7 Continuous Glucose Monitoring (CGM) System. People with Type 1 and Type 2 diabetes who are two years of age or older can take this medication. However, the diabetes devices and drugs market faces stringent regulatory hurdles and compliance requirements that hamper the growth of the market. Furthermore, the continuous advancements in genetics, biomarkers, and data analytics create lucrative market growth opportunities. These developments make it feasible to better understand patient reactions to different drugs on a deeper level.

Diabetes Devices and Drugs Market Size, Share, Trends | IGR

North America holds the largest market share in the diabetic devices and drugs market. A strong healthcare system, cutting-edge technology advancements, and a high rate of diabetes cases in the area are reasons for this dominant position. The well-established pharmaceutical and medical device businesses in North America also contribute significantly to the market's supremacy, consistently developing and introducing cutting-edge solutions for diabetes management. Furthermore, North America maintains its lead in this competitive market segment owing to a considerable focus on research and development, coupled with a strong consumer base seeking effective diabetic care. Moreover, the Asia Pacific emerged as the fastest-growing region in the diabetes devices and drugs market. The utilization of diabetes management techniques and pharmaceuticals is rising significantly across Asia Pacific due to increasing healthcare awareness and access to high-quality medical resources. This rapid growth can be attributed to several factors, notably the growing awareness and implementation of diabetic devices and drugs. Additionally, demographic changes and lifestyle shifts have led to a higher incidence of diabetes in the region, further propelling the demand for effective solutions. Businesses entering this market stand for growth unleash their creative potential, and thrive by meeting the diverse needs of the region's growing customer base.

Report Scope of the Diabetes Devices and Drugs Market:

Report Coverage Details
Market Size in 2022 USD 159.1 Billion
Market Size by 2030 USD 383.6 Billion
Growth Rate from 2023 to 2030 CAGR of 10.18%
Largest Market North America
No. of Pages 180
Market Drivers
  • The increase in product approvals and new product launches are propelling the growth of market.

  • The increasing patient suffering from diabetes is a significant driver of the market.

Market Segmentation By Type, and By End User
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global diabetes devices and drugs market covers segments such as type, and end user. On the basis of type, the sub-markets include devices, and drugs. On the basis of end user, the sub-markets include hospitals, clinics, ambulatory surgical centers, home care centers, and self-care.

The report provides profiles of the companies in the market such as Novo Nordisk A/S, Ypsomed AG, Abbott Laboratories, Ascensia Diabetes Care Holdings AG, Eli Lilly and Company, Hoffmann-La Roche Ltd., Johnson & Johnson, Medtronic, BD, Terumo Corporation, and others.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the diabetes devices and drugs market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global diabetes devices and drugs market was valued at USD 159.1 Billion in 2022.
It is likely to grow at a CAGR of 10.18% during the forecast period 2023-2030.
The global diabetes devices and drugs market is estimated to reach USD 383.6 Billion by the end of 2030.
North America is anticipated to exhibit high demand for diabetes devices and drugs market during the forecast period.
Novo Nordisk A/S, Ypsomed AG, Abbott Laboratories, Ascensia Diabetes Care Holdings AG, Eli Lilly and Company, Hoffmann-La Roche Ltd., Johnson & Johnson,Inc., Medtronic, BD, and Terumo Corporation.
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.